1. 首页
  2. 产品目录

Brivanib (BMS-540215),VEGFR2抑制剂

Brivanib (BMS-540215) （订货以英文为准）

编号：B127317
CAS号：649735-46-6
分子式：C19H19FN4O3
分子量：370.38
货号 品牌 包装 目录价 您的价格 库存 数量 购买
B127317-5mg 阿拉丁 5mg ¥179.90
请登录
B127317-50mg 阿拉丁 50mg ¥814.90
请登录
B127317-10mg 阿拉丁 10mg ¥267.90
请登录
B127317-100mg 阿拉丁 100mg ¥1383.90
请登录
产品名称 Brivanib (BMS-540215)
中文名称 Brivanib (BMS-540215),VEGFR2抑制剂
CAS号 649735-46-6
分子式（M.F.） C19H19FN4O3
分子量（M.W.） 370.38
储存条件 -20°C储存
溶解性Soluble in DMSO (74 mg/ml at 25 °C), water (<1 mg/ml at 25 °C), and ethanol (3 mg/ml at 25 °C).
存贮条件储存温度-20°C
应用An ATP-competitive inhibitor against VEGFR-2, Flk-1, VEGFR-1 and FGFR-1
产品介绍Brivanib (BMS-540215)是一种ATP竞争性的VEGFR2抑制剂，IC50为25 nM，对VEGFR-1和FGFR-1抑制作用适中，但比作用于PDGFR-β效果强240多倍。
备注Brivanib is an ATP-competitive inhibitor against VEGFR2 with IC50 of 25 nM, moderate potency against VEGFR-1 and FGFR-1, but >240-fold against PDGFR-β. Phase 3.
生化机理Brivanib is an ATP-competitive inhibitor against human VEGFR-2 and mouse Flk-1 with IC50 of 25 nM and 89 nM, respectively. Brivanib also inhibits VEGFR-1 and FGFR-1 with IC50 of 0.38 and 0.148 μM. Brivanib displays antitumor activities in H3396 xenograft. This compound completely inhibits the tumor growth, with TGI of 85% and 97%, respectively.
别名1-[[4-[(4-氟-2-甲基-1H-吲哚-5-基)氧基]-5-甲基吡咯并[2,1-f][1,2,4]三嗪-6-基]氧基]-2-丙醇; 酪氨酸激酶抑制剂;BMS-540215; BMS540215; BMS 540215;(2R)-1-[4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4 ]triazin-6-yloxy]propanol
搜索质检报告(COA)
搜索MSDS
相关产品